The invention provides a novel benzoxazepine compound of the general formula (I):wherein R1 and R2 are as defined in the specification or a stereoisomer, a geometric isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, or a polymorph thereof a process for its preparation and a pharmaceutical composition including an effective amount of the compound. The compounds are useful in the treatment of insulin resistance and clinical conditions associated therewith.
